Tumor necrosis factor-α (TNF-α) and TNF receptors (TNFR) are members of the growing TNF ligand and receptor families that are involved in immune regulation. The present report will focus on the role of the prototypic ligand TNF and its two receptors, TNFR1 and TNFR2, in viral pathogenesis. Although TNF was reported years ago to modulate viral infections, recent findings on the molecular pathways involved in TNFR signaling have allowed a better understanding of the molecular interactions between cellular and viral factors within the infected cell. The interactions of viral proteins with intracellular components downstream of the TNFR have highlighted at the molecular level how viruses can manipulate the cellular machinery to escape the immune response and to favor the spread of the infection. We will review here the role of TNF and TNFR in immune response and the role of TNF and TNFR signaling in viral pathogenesis.
Get full access to this article
View all access options for this article.
References
1.
BeutlerB, GreenwaldD, HulmesJD, ChangM, PanYCE, MathisonJ, UlevitchR, CeramiA.Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature316:552–554, 1985.
2.
BeutlerB, CeramiA.Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature320:584–588, 1986.
3.
CeramiA, BeutlerB.The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today9:28–31, 1988.
4.
BeutlerB, Van HuffelC.Unraveling function in the TNF ligand and receptor families. Science264:667–668, 1994.
5.
BazzoniF, BeutlerB.How do tumor necrosis factor receptors work?J Inflamm45:221–238, 1995.
6.
Hodge-DufourJ, MarinoMW, HortonMR, JungbluthA, BurdickMD, StrieterRM, NoblePW, HunterCA, PureA.Inhibition of interferon-γ-induced interleukin 12 production: A potential mechanism for the anti-inflammatory activities of tumor necrosis factor. Proc Natl Acad Sci U S A95:13806–13811, 1998.
HohmannHP, RemyR, BrockhausM, van LoonAP. Two different cell types have different major receptors for human tumor necrosis factor (TNF-α). J Biol Chem264:14927–14934, 1989.
9.
BrockhausM, SchoenfeldHJ, SchlaegerEJ, HunzikerW, LesslauerW, LoetscherH.Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc Natl Acad Sci U S A87:3127–3131, 1990.
10.
PorteuF, BrockhausM, WallachD, EngelmannH, NathanCF. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J Biol Chem266:18846–18853, 1991.
11.
GrellM, WajantH, ZimmermannG, ScheurichP.The type 1 receptor (CD 120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A95:570–575, 1998.
12.
GrellM, DouniE, WajantH, LohdenM, ClaussM, MaxeinerB, GeorgopoulosS, LesslauerW, KolliasG, PfizenmaierK, ScheurichP.The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80-kDa tumor necrosis factor receptor. Cell83:793–802, 1995.
13.
TartagliaLA, PennicaD, GoeddelDV. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem268:18542–18548, 1993.
14.
GrellM, BeckeFM, WajantH, MannelDN, ScheurichP.TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur J Immunol28:257–263, 1998.
15.
HaridasV, DarnayBG, NatarajanK, HellerR, AggarwalBB. Over-expression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-κB activation, and c-Jun kinase activation. J Immunol160:3152–3162, 1998.
16.
EspevikT, BrockhausM, LoetscherH, NonstadU, ShalabyR.Characterization of binding and biological effects of monoclonal antibodies against human tumor necrosis factor receptor. J Exp Med171:415–426, 1990.
17.
WiegmannK, SchutzeS, KampenE, HimmlerA, MachleidtT, KronkeM.Human 55-kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J Biol Chem267:17997–18001, 1992.
18.
WeissT, GrellM, SiemienskiK, MuhlenbeckF, DurkopH, PfizenmaierK, ScheurichP, WajantH.TNFR80-dependent enhancement of TNFR60-induced cell death is mediated by TNFR-associated factor 2 and is specific for TNFR60. J Immunol161:3136–3142, 1998.
19.
GehrG, GentzR, BrockhausM, LoetscherH, LesslauerW.Both tumor necrosis factor receptors mediate proliferative signals in human mononuclear cell activation. J Immunol149:911–917, 1992.
20.
VandenabeeleP, DeclercqW, Van VercammenD, de CraenM, GrootenJ, LoetscherH, BrockhausM, LesslauerW, FiersW.Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T-cell hybridoma. J Exp Med176:1015–1024, 1992.
21.
JacobsenFW, RotheM, RustenL, GoeddelDV, SmelandEB, VeibyOP, SlordaliL, JacobsenSEW. Role of the 75-kDa tumor necrosis factor (TNF) receptor Inhibition of early hematopoiesis. Proc Natl Acad Sci U S A91:10695–10699, 1994.
22.
ZhengL, FisherG, MillerRE, PeschonJ, LynchDH, LenardoMJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature377:348–351, 1995.
23.
BoiseLH, Gonzalez-GarciaM, PostemaCE, DingL, LindstenT, TurkaLA, MaoX, NunezG, ThompsonCB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell74:597–608, 1993.
24.
LinRH, HwangYW, YangBC, LinCS. TNF receptor 2–triggered apoptosis is associated with the downregulation of Bcl-xL on activated T cells and can be prevented by CD28 costimulation. J Immunol158:598–603, 1997.
25.
NopharY, KemperO, BrakebuschC, EnglemannH, ZwangR, AderkaD, HoltmannH, WallachD.Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J9:3269–3278, 1990.
26.
SeckingerP, IsaazS, DayerJM. Purification and biologic characterization of a specific tumor necrosis factor-a inhibitor. J Biol Chem264:11966–11973, 1989.
27.
EngelmannH, HoltmannH, BrakebuschC, AvniYS, SarovI, NopharY, HadasE, LeitnerO, WallachD.Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem265:14497–14504, 1990.
28.
MohlerKM, SleathPR, FitznerJN, CerrettiDP, AldersonM, KerwarSS, TorranceDS, Otten-EvansC, GreenstreetT, WeerawarnaK.Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature370:218–220, 1994.
29.
AderkaD, EngelmannH, MaorY, BrakebuschC, WallachD.Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med175:323–329, 1992.
30.
GatanagaT, HwangCD, GatanagaM, CappucciniF, YamamotoRS, GrangerGA. The regulation of TNF receptor mRNA synthesis, membrane expression, and release by PMA- and LPS-stimulated human monocytic THP-1 cells in vitro.Cell Immunol138:1–10, 1991.
31.
LeeuwenbergJF, DentenerMA, BuurmanWA. Lipopolysaccharide (LPS)-mediated soluble TNF receptor release and TNF receptor expression by monocytes: Role of CD 14, LPS binding protein, and bactericidal/permeability-increasing protein. J Immunol152:5070–5076, 1994.
32.
KalinkovichA, EngelmannH, HarpazN, BursteinR, BarakV, KalickmanI, WallachD, BentwichZ.Elevated serum levels of soluble tumour necrosis factor receptors (sTNFR) in patients with HIV infection. Clin Exp Immunol89:351–355, 1992.
33.
HoberD, BenyoucefS, DelannoyAS, de GrooteD, AjanaF, MoutonY, WattreP.High plasma level of soluble factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients. Infection24:213–217, 1996.
34.
NoktaM, RosseroR, LoeschK, PollardRB. Kinetics of tumor necrosis factor-α and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didnosine, and hydroxyurea. AIDS Res Hum Retroviruses13:1633–1638, 1997.
35.
AderkaD, WysenbeekA, EngelmannH, CopeAP, BrennanF, MoladY, HornikV, LevoY, MainiRN, FeldmannM.Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum36:1111–1120, 1993.
36.
ChikanzaIC, Roux-LombardP, DayerJM, PanayiGS. Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis, and osteoarthritis. Clin Exp Immunol92:19–22, 1993.
37.
LazdinsJK, GrellM, WalkerMR, Woods-CookK, ScheurichP, PfizenmaierK.Membrane tumor necrosis factor (TNF)- induced cooperative signaling of TNFR60 and TNFR80 favors induction of cell death rather than virus production in HIV-infected T cells. J Exp Med185:81–90, 1997.
38.
TartagliaLA, WeberRF, FigariIS, ReynoldsC, PalladinoMAJ, GoeddelDV. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc Natl Acad Sci U S A88:9292–9296. 1991.
39.
BegAA, BaltimoreD.An essential role for NF-κB in preventing TNF-α-induced cell death. Science274:782–784, 1996.
40.
WangCY, MayoMW, BaldwinASJr. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κB. Science274:784–787, 1996.
41.
Van AntwerpDJ, MartinSJ, KafriT, GreenDR, VermaIM. Suppression of TNF-α-induced apoptosis by NF-κB. Science274:787–789, 1996.
42.
RoulstonA, ReinhardC, AmiriP, WilliamsLT. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor-α. J Biol Chem273:10232–10239, 1998.
43.
GrussHI, DowerSK. The TNF ligand superfamily and its relevance for human diseases. Cytokines Mol Ther1:75–105, 1995.
44.
HsuH, XiongJ, GoeddelDV. The TNF receptor I-associated protein TRADD signals cell death and NF-κB activation. Cell81:495–504, 1995.
45.
RotheM, PanMG, HenzelWJ, AyresTM, GoeddelDV. The TNFR2–TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell83:1243–1252, 1995.
46.
HsuH, ShuHB, PanMG, GoeddelDV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell84:299–308, 1996.
47.
TingAT, Pimentel-MuinosFX, SeedB.RIP mediates tumor necrosis factor receptor 1 activation of NF-κB but not Fas/APO-1-initiated apoptosis. EMBO J15:6189–6196, 1996.
48.
ChinnaiyanAM, TepperCG, SeidinMF, O'RourkeK, KischkelFC, HellbardtS, KrammerPH, PeterME, DixitVM. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem271:4961–4965, 1996.
49.
VarfolomeevE, BoldinM, GoncharovT, WallachD.A potential mechanism of “cross-talk” between the p55 tumor necrosis factor receptor and Fas/APO1: Proteins binding to the death domains of the two receptors also bind to each other. J Exp Med183:1271–1275, 1996.
50.
MalininNL, BoldinMP. KovalenkoAV, WallachD.MAP3K-related kinase involved in NF-κB induction by TNF, CD95, and IL-1. Nature385:540–544. 1997.
51.
RegnierCH, SongtHY, GaoX, GoeddelDV, CaoZ, RotheM.Identification and characterization of an I-κB kinase. Cell90:373–383. 1997.
52.
DiDonatoJA, HayakawaM, RothwharfDM, ZandiE, KarinM.A cytokine-responsive I-κB kinase that activates the transcription factor NF-κB. Nature388:548–554, 1997.
ZandiE, RothwarfDM, DelhareM, HayakawaM, KarinM.The I-κB kinase (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for I-κB phosphorylation and NF-κB activation. Cell91:243–252, 1997.
55.
WoroniczJD, GaoX, CaoZ, RotheM, GoeddelDV. I-κB kinase-β: NF-κB activation and complex formation with I-κB kinase-α and NIK. Science278:866–869, 1997.
56.
LiuZG, HsuH, GoeddelD, KarinM.Dissection of TNF-receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell87:565–576, 1996.
57.
NatoliG, CostanzoA, IanniA, TempletonDJ, WoodgettJR, BalsanoC, LevreroM.Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF-2-dependent pathway. Science275:200–203, 1997.
58.
SongH, RegnierC, KirschningC, GoeddelD, RotheM.Tumor necrosis factor (TNF)-mediated kinase cascades: Bifucation of nuclear factor-κB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2. Proc Natl Acad Sci U S A94:9792–9796, 1997.
59.
YehWC, ShahinianA, SpeiserD, KraunusJ, BilliaF, WakehamA, de la PompaJL, FerrickD, HumB, IscoveN, OhashiP, RotheM, GoeddelDV, MakTW. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2–deficient mice. Immunity7:715–725, 1997.
60.
LeeSY, ReichlinA, SantanaA, SokolKA, NussenzweigMC, ChoiY.TRAF2 is essential for JNK but not NF-κB activation and regulates lymphocyte proliferation and survival. Immunity7:703–7131997.
61.
KelliherMA, GrimmS, IshidaY, KuoF, StangerBZ, LederP.The death domain kinase RIP mediates the TNF-induced NF-κB signalImmunity8:297–303, 1998.
62.
ShuHB, TakeuchiM, GoeddelDV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A93:13973–13978, 1996.
63.
YehWC, PompaJL, McCurrachME, ShuHB, EliaAJ. ShahinianA, NgM, WakehamA, KhooW, MitchellK, El-DeiryWS, LoweSW, GoeddelDV, MakTW. FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis. Science279:1954–1958, 1998.
64.
DuanH, DixitVM. RAIDD is a new “death” adapter molecule. Nature385:86–89, 1997.
65.
JiangY, WoroniczJD, LiuW, GoeddelDV. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. Science283:543–546, 1999.
66.
SingA, NiJ, AggarwalBB. Death domain receptors and their role in cell demise. J Interferon Cytokine Res18:439–450, 1998.
67.
SalvesenGS, DixitVM. Caspases: Intracellular signaling by proteolysis. Cell91:443–446, 1997.
68.
SleeEA, HarteMT, KluckRM, WolfBB, CasianoCA, NewmeyerDD, WangHG, ReedJC, NicholsonDW, AlnemriES, GreenDR, MartinSJ. Ordering the cytochrome-c-initiated caspase cascade: Hierarchical activation of caspases-2, −3, −6, −7, −8, and −10 in a caspase-9-dependent manner. J Cell Biol144:281–292. 1999.
69.
GreenDR, ReedJC. Mitochondria and apoptosis. Science281:1309–1312, 1998.
PrendergastGC. Mechanisms of apoptosis by c-Myc.Oncogene18:2967–2987, 1999.
72.
SchreiberM, RajarathnamK, McFaddenG.Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF-α, but the dimer is a more potent TNF inhibitor. J Biol Chem271:13333–13341, 1996.
73.
SchreiberM, SedgerL, McFaddenG.Distinct domains of M-T2, the myxoma virus tumor necrosis factor (TNF) receptor homolog, mediate extracellular TNF binding and intracellular apoptosis inhibition. J Virol71:2171–2181, 1997.
74.
ZhouQ, SnipasS, OrthK, MuzioM, DixitVM, SalvesenGS. Target protease specificity of the viral serpin CrmA: Analysis of five caspases. J Biol Chem272:7797–7800, 1997.
75.
KettleS, AlcamiA, KhannaA, EhretR, JassoyC, SmithGL. Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-IB-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1β-induced fever. J Gen Virol78:677–685, 1997.
76.
PauloseM, BennettBL, ManningAM, EssaniK.Selective inhibition of TNF-α induced cell adhesion molecule gene expression by tanapox virus. Microb Pathog25:33–41, 1998.
77.
IzumiKM, KayeKM, KieffED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A94:1447–1452, 1997.
78.
SyllaBS, HungSC, DavidsonDM, HatzivassiliouE, MalininNL, WallachD, GilmoreTD, KieffE, MosialosG.Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the I-κB kinases IKK-α and IKK-β. Proc Natl Acad SciU S A95:10106–10111, 1998.
79.
DevergneO, McFarlandEC, MosialosG, IzumiKM, WareCF, KieffE.Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol72:7900–7908, 1998.
80.
MosialosG, BirkenbachM, YalamanchiliR, VanArsdaleT, WareC, KieffE.The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the rumor necrosis factor receptor family. Cell80:389–399, 1995.
81.
SandbergM, HammerschmidtW, SugdenB.Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol71:4649–4656, 1997.
82.
KayeKM, DevergneO, HaradaJN, IzumiKM, YalamanchiliR, KieffE, MosialosG.Tumor necrosis factor receptor associated factor 2 is a mediator of NF-κB activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci U S A93:11085–11090, 1996.
83.
KilgerE, KieserA, BaumannM, HammerschmidtW.Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J17:1700–1709, 1998.
84.
LiebowitzD.Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med338:1413–1421, 1998.
85.
KawanishiM.Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor-α and anti-Fas antibody. J Virol71:3319–3322, 1997.
86.
LayJD, TsaoCI, ChenJY, KadinME, SuIJ. Upregulation of tumor necrosis factor-a gene by Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome. J Clin Invest100:1969–1979, 1997.
87.
Rossol-VothR, RossolS, SchuttKH, CorridoriS, de CianW, FalkeD.In vivo protective effect of tumour necrosis factor-α against experimental infection with herpes simplex virus type 1. J Gen Virol72:143–147, 1991.
88.
DeleroGC, MarcatiliA, FolgoreA, DonnarummaG, PetrilloG.TNF-α expression and herpes simplex infection in human monocytes treated with growth hormone, prolactin, and insulin. Microbiologica21:213–220, 1998.
89.
GalvanV, BrandimartiR, RoizmanB.Herpes simplex virus 1 blocks caspase-3-independent and caspase-dependent pathways to cell death. J Virol73:3219–3226, 1999.
90.
MontgomeryRI, WarnerMS, LumBJ, SpearPG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell87:427–436, 1996.
91.
WhitbeckJC, PengC, LouH, XuR, WillisSH, Ponce de LeonM, PengT, NicolaAV. MontgomeryRI, WarnerMS, SoulikaAM, SpruceLA, MooreWT, LambrisJD, SpearPG, CohenGH, EisenbergRJ. Glycoprotein D of herpes simplex virus (HSV) binds directly to HVEM, a member of the tumor necrosis factor receptor superfamily and a mediator of HSV entry. J Virol71:6083-6093, 1997.
92.
Terry-AllisonT, MontgomeryRI, WhitbeckJC, XuR, CohenGH, EisenbergRJ, SpearPG. HveA (herpesvirus entry mediator A), a co-receptor for herpes simplex virus entry, also participates in virus-induced cell fusion. J Virol72:5802–5810, 1998.
93.
MarstersSA, AyresTM, SkubatchM, GrayCL, RotheM, AshkenaziA.Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-κB and AP-1. J Biol Chem272:14029–14032, 1997.
94.
MauriDN, EbnerR, MontgomeryRI, KochelKD, CheungTC, YuGL, RubenS, MurphyM, EisenbergRJ, CohenGH, SpearPG, WareCF. LIGHT, a new member of the TNF superfamily, and lymphotoxin-α are ligands for herpesvirus entry mediator. Immunity8:21–30, 1998.
95.
SteinJ, VolkHD, LiebenthalC, KrugerDH, ProschS.Tumour necrosis factor-α stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Virol74:2333–2338, 1993.
96.
GeistLJ, MonickMM, StinskiMF, HunninghakeGW. The immediate early genes of human cytomegalovirus upregulate tumor necrosis factor-α gene expression. J Clin Invest93:474–478, 1994.
97.
SmithPD, SainiSS, RaffeldM, ManischewitzJF, WahlSM. Cytomegalovirus induction of tumor necrosis factor-α by human monocytes and mucosal macrophages. J Clin Invest90:1642–1648, 1992.
98.
DavignonJL, CastanieP, YorkeJA, GautierN, ClementD, DavrincheC.Anti-human cytomegalovirus activity of cytokines produced by CD4+ T-cell clones specifically activated by IE1 peptides in vitro.J Virol70:2162–2169, 1996.
99.
LucinP, JonjicS, MesserleM, PolieB, HengelH, KoszinowskiUH. Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-γ and tumour necrosis factor. J Gen Virol75:101–110, 1994.
100.
YerkovichST, OlverSD, LenzoJC, PeacockCD, PriceP.The roles of tumour necrosis factor-α, interleukin-1, and interleukin-12 in murine cytomegalovirus infection. Immunology91:45–52, 1997.
101.
PavicI, PolicB, CrnkovicI, LucinP, JonjicS, KoszinowskiUH. Participation of endogenous tumour necrosis factor-α in host resistance to cytomegalovirus infection. J Gen Virol74:2215–2223, 1993.
102.
OrangeJS, Salazar-MatherTP, OpalSM, BironCA. Mechanisms for virus-induced liver disease: Tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol71:9248–9258, 1997.
103.
LeeH, ChoiJK, LiMT, KayeK, KieffE, JungJU. Role of cellular tumor necrosis factor receptor-associated factors in NF-κB activation and lymphocyte transformation by herpesvirus Saimiri STP. J Virol73:3913–3919, 1999.
104.
SuF, SchneiderRJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor-α. Proc Natl Acad Sci U S A94:8744–8749, 1997.
105.
Lara-PezziE, MesillaAL, MajanoPL, RedondoJM, Lopez-CabreraM.The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. EMBO J17:7066–7077, 1998.
106.
FangJW, ShenWW, MeagerA, LauJY. Activation of the tumor necrosis factor-α system in the liver in chronic hepatitis B virus infection. Am J Gastroenterol91:748–753, 1996.
107.
GuidottiLG, BorrowP, HobbsMV, MatzkeB, GresserI, OldstoneMB, ChisariFV. Viral cross talk: Intracellular activation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A93:4589–4594, 1996.
108.
GuidottiLG, BorrowP, BrownA, McClaryH, KochR, ChisariFV. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med189:1555–1564, 1999.
109.
GuidottiLG, RochfordR, ChungJ, ShapiroM, PurecllR, ChisariFV. Viral clearance without destruction of infected cells during acute HBV infection. Science284:825–829, 1999.
110.
HohlerT, KrugerA, GerkenG, SchneiderPM, Meyer zum BuschenefeldeKH, RittnerC.A tumor necrosis factor-α (TNF-α) promoter polymorphism is associated with chronic hepatitis B infection. Clin Exp Immunol111:579–582, 1998.
111.
Lopez-GuerreroJA, RayetB, TuynderM, RommelaereJ, DinsartC.Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection. Blood89:1642–1653, 1997.
112.
RayetB, Lopez-GuerreroJA, RommelaereJ, DinsartC.Induction of programmed cell death by parvovirus H-1 in U937 cells: Connection with the tumor necrosis factor-α signaling pathway. J Virol72:8893–8903, 1998.
FauciAS. Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science262:1011–1018, 1993.
115.
LahdevirtaJ, MauryCP, TeppoAM, RepoH.Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med85:289–291, 1988.
116.
HerbeinG, MontanerLJ, GordonS.Tumor necrosis factor-α inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: A selective role for the 75-kDa receptor. J Virol70:7388–7397, 1996.
117.
KarstenV, GordonS, KimA, HerbeinG.HIV-1 envelope glycoprotein gp120 downregulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor-α. Immunology88:55–60, 1996.
118.
HerbeinG, DoyleAG, MontanerLJ, GordonS.Lipopolysaccharide (LPS) downregulates CD4 expression in primary human macrophages through induction of endogenous tumor necrosis factor (TNF) and IL-1β. Clin Exp Immunol102:430–437, 1995.
119.
SallustoF, LenigD, MackayCR, LanzavecchiaA.Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med187:875–883, 1998.
120.
SchmidtmayerovaH, NottetHS, NuovoG, RaabeT, FlanaganCR, DubrovskyL, GendelmanHE, CeramiA, BukrinskyM, SherryB.Human immunodeficiency virus type 1 infection alters chemokine-β peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci U S A93:700–704, 1996.
121.
DiMarzioP, TseJ, LandauNR. Chemokine receptor regulation and HIV type 1 tropism in monocyte-macrophages. AIDS Res Hum Retroviruses14:129–138, 1998.
122.
LoetscherH, StueberD, BannerD, MackayF, LesslauerW.Human tumor necrosis factor-α (TNF-α) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors. J Biol Chem268:26350–26357, 1993.
123.
DuhEJ, MauryWJ, FolksTM, FauciAS, RabsonAB. Tumor necrosis factor-α activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-κB sites in the long terminal repeat. Proc Natl Acad Sci U S A86:5974–5978, 1989.
124.
OsbomL, KunkelS, NabelGJ. Tumor necrosis factor-α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor-κB. Proc Natl Acad Sci U S A86:2336–2340, 1989.
125.
PoliG, KinterA, JustementS, KebrlJH, BresslerP, StanleyS, FauciAS. Tumor necrosis factor-α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci U S A87:782–785, 1990.
126.
ButeraST, RobertsBD, LeungK, NabelGJ, FolksTM. Tumor necrosis factor receptor expression and signal transduction in HIV-1 infected cells. AIDS7:911–918, 1993.
127.
HerbeinG, GordonS.55- and 75-kDa tumor necrosis factor receptors mediate distinct actions in regard to human immunodeficiency virus type 1 replication in primary human macrophages. J Virol71:4150–4156, 1997.
128.
OrensteinJM, FoxC, WahlSM. Macrophages as a source of HIV during opportunistic infections. Science276:1857–1861, 1997.
129.
ZybarthG, ReilingN, SchmidtmayerovaH, SherryB, BukrinskyM.Activation-induced resistance of human macrophages to HIV-1 infection in vitro.J Immunol162:400–406, 1999.
130.
AlfanoM, SchmidtmayerovaH, BukrinskyM.Bacterial lipopolysaccharide is a potent inhibitor of HIV-1 replication in T lymphocytes and macrophages. AIDS12:1724–1726, 1998.
131.
MargolickJB, MunozA, DonnenbergAD, ParkLP. GalaiN, GiorgiJV, O'GormanMR, FerbasJ.Failure of T-cell homeostasis preceding AIDS in HIV-1 infection: The Multiple AIDS Cohort Study. Nat Med1:674–680, 1995.
132.
HerbeinG, MahlknechtU, BatliwallaF, GregersenP, PappasT, ButlerJ, O'BrienWA, VerdinE.Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature395:189–194, 1998.
133.
HerbeinG, Van LintC, LovettJL, VerdinE.Distinct mechanisms trigger apoptosis in human immunodeficiency virus type 1-infected and in uninfected bystander T lymphocytes. J Virol72:660–670, 1998.
134.
YuXF, WangZ, VlahovD, MarkhamRB, FarzadeganH, MargolickJB. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T-cell decline and disease progression in injection drug users. J Infect Dis178:388–396, 1998.
135.
SomasundaranM, RobinsonHL. A major mechanism of human immunodeficiency virus-induced cell killing does not involve cell fusion. J Virol61:3114–3119, 1987.
136.
GandhiRT, ChenBK, StrausSE, DaleJK, LenardoMJ, BaltimoreD.HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism. J Exp Med187:1113–1122, 1998.
137.
LifsonJD, ReyesGR, McGrathMS, SteinBS, EnglemanEG. AIDS retrovirus induced cytopathology: Giant cell formation and involvement of CD4 antigen. Science232:1123–1127, 1986.
138.
SodroskiJ, GohWC, RosenC, TartarA, PortetelleD, BurnyA, HaseltineW.Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science231:1549–1553, 1986.
139.
YoffeB, LewisDE, PetrieBL, NoonanCA, MelnickJL, HollingerFB. Fusion as a mediator of cytolysis in mixtures of uninfected CD4+ lymphocytes and cells infected by human immunodeficiency virus. Proc Natl Acad Sci U S A84:1429–1433, 1987.
140.
GoldingH, RobeyFA, GatesFTIII, LinderW, BeiningPR, HoffmanT, GoldingB.Identification of homologous regions in human immunodeficiency virus 1 gp41 and human MHC class II βl domain. I. Monoclonal antibodies against the gp41–derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med167:914–923, 1988.
141.
ZinkemagelRM, HengartnerH.T-cell-mediated immunopathology versus direct cytolysis by virus: Implications for HIV and AIDS. Immunol Today15:262–268, 1994.
142.
ImbertiL, SottiniA, BettinardiA, PuotiM, PrimiD.Selective depletion in HIV infection of T cells that bear specific T-cell receptor Vβ sequences. Science254:860–862, 1991.
143.
AmeisenJC, CapronA.Cell dysfunction and depletion in AIDS: The programmed cell death hypothesis. Immunol Today12:102–1051991.
144.
Laurent-CrawfordAG, KrustB, MullerS, RiviereY, Rey-CuilleMA, BechetJM, MontagnierL, HovanessianAG. The cytopathic effect of HIV is associated with apoptosis. Virology185:829–8391991.
145.
MartinSJ, MatearPM, VyakarnamA.HIV-1 infection of human CD4+ T cells in vitro: Differential induction of apoptosis in these cells. J Immunol152:330–342, 1994.
146.
TeraiC, KornbluthRS, PauzaCD, RichmanDD, CarsonDA. Apoptosis as a mechanism of cell death in culture T lymphoblasts acutely infected with HIV-1. J Clin Invest87:1710–1715, 1991.
147.
GougeonML, GarciaS, HeeneyJ, TschoppR, LecoeurH, GuetardD, RameV, DauguetC, MontagnierL.Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses9:553–563, 1993.
148.
GrouxH, TorpierG, MonteD, MoutonY, CapronA, AmeisenJC. Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med175:331–340, 1992.
149.
LewisDE, TangDS, Adu-OppongA, SchoberW, RodgersJR. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol153:412–420, 1994.
150.
OyaizuN, McCloskeyTW, CoronesiM, ChirmuleN, KalyanaramanVS, PahwaS.Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type 1-infected patients and in CD4 cross-linked PBMCs from normal individuals. Blood82:3392–3400, 1993.
151.
FinkelTH, Tudor-WilliamsG, BandaNK, CottonMF, CurielT, MonksC, BabaTW, RuprechtRM, KupferA.Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med1:129–134, 1995.
152.
BadleyAD, McEhlinnyJA, LeibsonPJ, LynchDH, AldersonMR, PayaCV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol70:199–206, 1996.
153.
BadleyAD, DockrellD, SimpsonM, SchutR, LynchDH, LeibsonP, PayaCV. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med185:55–64, 1997.
154.
OyaizuN, McCloskeyTW, ThanS, HuR, KalyanaramanVS, PahwaS.Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-γ and tumor necrosis factor-α secretion. Blood84:2622–2631, 1994.
155.
WileySR, SchooleyK, SmolakPJ, DinWS, HuangCP, NichollJK, SutherlandGR, SmithTD, RauchC, SmithCA, GoodwinRG. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity3:673–682, 1995.
156.
PittiRM, MarstersSA, RuppertS, DonahueCJ, MooreA, AshkenaziA.Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem271:12687–12690, 1996.
157.
LewisDE, Ng TangDS, WangX, KozinetzC.Co-stimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV. Clin Immunol90:302–312, 1999.
158.
AmeisenJC. Setting death in motion. Nature395:117–119, 1998.
159.
RayRB, MeyerK, SteeleR, ShrivastavaA, AggarwalBB, RayR.Inhibition of tumor necrosis factor (TNF-α)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem273:2256–2259, 1998.
160.
MarusawaH, HijikataM, ChibaT, ShimotohnoK.Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor α-mediated apoptosis via NF-kB activation. J Virol73:4713–4720, 1999.
161.
YouLR, ChenCM, LeeYHW. Hepatitis C virus core protein enhances NF-κB signal pathway triggering by lymphotoxin-β receptor ligand and tumor necrosis factor-α. J Virol73:1672–1681, 1999.
162.
ZhuN, KhoshnanA, SchneiderR, MatsumotoM, DennertG, WareC, LaiMM. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol72:3691–3697, 1998.
163.
NelsonDR, LimHL, MarousisCG, FangJW, DavisGL, ShenL, UrdeaMS, KolbergJA, LauJY. Activation of tumor necrosis factor-α system in chronic hepatitis C virus infection. Digestive Dis Sci42:2487–2494, 1997.
164.
KallinowskiB, HaserothK, MarinosG, HanckC, StremmelW, TheilmannL, SingerMW, RossolS.Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol111:269–277, 1998.
165.
HohlerT, KrugerA, GerkenG, SchneiderPM, Meyer zum BuschenfeldeKH, RittnerC.Tumor necrosis factor-α promoter polymorphism at position 238 is associated with chronic active hepatitis C infection. J Med Virol54:173–177, 1998.
166.
RobertsNJJr., NicholsJE. Regulation of lymphocyte proliferation after influenza virus infection of human mononuclear leukocytes. J Med Virol27:179–187, 1989.
167.
MockDJ, RobertsNJJr. Role of the monocyte-macrophage in influenza virus infection of lymphocytes: Implication for HIV infection. AIDS Res Hum Retroviruses6:965–966, 1990.
168.
HofmannP, SprengerH, KaufmannA, BenderA, HasseC, NainM, GemsaD.Susceptibility of mononuclear phagocytes to influenza A virus infection and possible role in the antiviral response. J Leukoc Biol61:408–414, 1997.
169.
SarenevaT, MatikainenS, KurimotoM, JulkunenI.Influenza A virus-induced IFN-α/β and IL-18 synergistically enhance IFN-γ gene expression in human T cells. J Immunol160:6032–6038, 1998.
170.
GongJH, SprengerH, HinderF, BenderA, SchmidtA, HorchS, NainM, GemsaD.Influenza A virus infection of macrophages: Enhanced tumor necrosis factor-α (TNF-α) gene expression and lipopolysaccharide-triggered TNF-α release. J Immunol147:3507–3513, 1991.
171.
LehmannC, SprengerH, NainM, BacherM, GemsaD.Infection of macrophages by influenza A virus: Characteristics of tumour necrosis factor-α (TNF-α) gene expression. Res Virol147:123–130, 1996.
172.
NainM, HinderF, GongJH. SchmidtA, BenderA, SprengerH, GemsaD.Tumor necrosis factor-α production of influenza A virus-infected macrophages and potentiating effect of lipopolysaccharide. J Immunol145:1921–1928, 1990.
173.
BenderA, AmannU, JagerR, NainM, GemsaD.Effect of granulocyte/macrophage colony-stimulating factor on human monocytes infected with influenza A virus: Enhancement of virus replication, cytokine release, and cytotoxicity. J Immunol151:5416–5424, 1993.
174.
BrownEL, WootersJL, FerenzCR, O'BrienCM, HewickRM, HerrmannSH. Characterization of peptide binding to the murine MHC class 1 H-2Kk molecule: Sequencing of the bound peptides and direct binding of synthetic peptides to isolated class I molecules. J Immunol153:3079–3092, 1994.
175.
KuwanoK, KawashimaT, AraiS.Antiviral effect of TNF-α and IFN-γ7 secreted from a CD8+ influenza virus-specific CTL clone. Viral Immunol6:1–11, 1993.
176.
Van CampenH.Influenza A virus replication is inhibited by tumor necrosis factor-α in vitro.Arch Virol136:439–446, 1994.
BeckerS, QuayJ, SoukupJ.Cytokine (tumor necrosis factor, IL-6, and IL-8) production by respiratory syncytial virus-infected human alveolar macrophages. J Immunol147:4307–4312, 1991.
179.
CirinoNM, PanuskaJR, VillaniA, TarafH, RebertNA, MerollaR, TsivitseP, GilbertIA. Restricted replication of respiratory syncytial virus in human alveolar macrophages. J Gen Virol74:1527–1537, 1993.
180.
ArnoldR, KonigB, GalattiH, WerchauH, KonigW.Cytokine (IL-8, IL-6, TNF-α) and soluble TNF receptor-1 release from human peripheral blood mononuclear cells after respiratory syncytial virus infection. Immunology85:364–372, 1995.
181.
PatelJA, JiangZ, NakajimaN, KunimotoM.Autocrine regulation of interleukin-8 by interleukin-1α in respiratory syncytial virus-infected pulmonary epithelial cells in vitro.Immunology95:501–506, 1998.
182.
JiangZ, KunimotoM, PatelJA. Autocrine regulation and experimental modulation of interleukin-6 expression by human pulmonary epithelial cells infected with respiratory syncytial virus. J Virol72:2496–2499, 1998.
183.
PanuskaJR, MerollaR, RebertNA, HoffmannSP, TsivitseP, CirinoNM, SilvermanRH, RankinJA. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages: Suppression of early cytokine production and implications for incomplete immunity. J Clin Invest96:2445–2453, 1995.
184.
FiedlerMA, Wernke-DollriesK.Incomplete regulation of NF-κB by I-κBa during respiratory syncytial virus infection in A549 cells. J Virol73:4502–4507, 1999.
185.
JamaluddinM, CasolaA, GarofaloRP, HanY, ElliottT, OgraPL, BrasierAR. The major component of I-κBa proteolysis occurs independently of the proteosome pathway in respiratory syncytial virus-infected pulmonary epithelial cells. J Virol72:4849–4857, 1998.
186.
LangedijkJP, de GrootBL, BerendsenHJ, van OirschotJT. Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor. Virology243:293–302, 1998.
187.
FinkeD, BrinckmannUG, ter MeulenV, LiebertUG. γ-Interferon is a major mediator of antiviral defense in experimental measles virus-induced encephalitis. J Virol69:5469–5474, 1995.
188.
MassaPT, SchimplA, WeckerE, ter MeulenV.Tumor necrosis factor amplifies measles virus-mediated la induction on astrocytes. Proc Natl Acad Sci U S A84:7242–7245, 1987.
189.
Dhib-JalbutSS, CowanEP. Direct evidence that interferon-β mediates enhanced HLA-class I expression in measles virus-infected cells. J Immunol151:6248–6258, 1993.
190.
Dhib-JalbutSS, XiaQ, DrewPD, SwovelandPT. Differential upregulation of HLA class I molecules on neuronal and glial cell lines by virus infection correlates with differential induction of IFN-β. J Immunol155:2096–2108, 1995.
191.
Dhib-JalbutS, XiaJ, RangaviggulaH, FangYY, LeeT.Failure of measles virus to activate nuclear factor-κB in neuronal cells: Implications on the immune response to viral infections in the central nervous system. J Immunol162:4024–4029, 1999.
192.
WongGHW, GoeddelDV. Tumour necrosis factor-α and β inhibit virus replication and synergize with interferons. Nature323:819–822, 1986.
193.
KoyamaAH, ArakawaT, AdachiA.Acceleration of virus-induced apoptosis by tumor necrosis factor. FEBS Lett426:179–182, 1998.
194.
GagnonSJ, EnnisFA, RothmanAL. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4+ cytotoxic T lymphocyte clones. J Virol73:3623–3629, 1999.
